Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
by Kinjel Shah
Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
The Zacks Analyst Blog Highlights: Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc
by Zacks Equity Research
Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc are highlighted in this Analyst Blog article.
Top Analyst Reports for Bank of America, Broadcom & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Broadcom Inc. (AVGO), and Royal Dutch Shell plc (RDS.A).
Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?
by Zacks Equity Research
Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Is Vertex (VRTX) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $223.96 in the latest trading session, marking a +0.95% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $221.86 in the latest trading session, marking a -0.3% move from the prior day.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $223.32 in the latest trading session, marking a +0.63% move from the prior day.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $215.41, moving +0.41% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $209.24, marking a +0.52% move from the previous day.
The Zacks Analyst Blog Highlights: Microsoft, NVIDIA, Medtronic, The Progressive and Vertex Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, NVIDIA, Medtronic, The Progressive and Vertex Pharma
Top Stock Reports for Microsoft, NVIDIA & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), NVIDIA Corporation (NVDA), and Medtronic plc (MDT).
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Why Is Vertex (VRTX) Up 8.4% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
by Zacks Equity Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II
by Zacks Equity Research
Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.
Vertex Pharmaceuticals (VRTX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Vertex Pharmaceuticals (VRTX) Just Reclaimed the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation
by Zacks Equity Research
The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.
CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug
by Zacks Equity Research
CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.
Wall Street Analysts Think Vertex (VRTX) Could Surge 36%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Vertex (VRTX) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold
by Zacks Equity Research
Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.
Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down
by Zacks Equity Research
Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.